What will Nasdaq 100 (NDX) hit in March?
Market Description
What will Nasdaq 100 (NDX) hit in March?
Related News
Yokneam Illit, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- Wearable Devices Ltd. (Nasdaq: WLDS, WLDSW) ('Wearable Devices” or the 'Company”), a technology growth company specializing in artificial intelligence ('AI”)-powered touchless sensing wearables, today announced a significant expansion of its AI expert advisory board. This strategic enhancement strengthens the Company's commitment to advancing neural AI innovation through ai6 Labs.
Hong Kong-based K‑Tech and Calgary’s Aurora AZ Energy form joint venture to power large‑scale AI, HPC and crypto mining operations in Alberta with low‑cost wellhead natural gas.
SINGAPORE, March 16, 2026 (GLOBE NEWSWIRE) -- Bitdeer Technologies Group (NASDAQ: BTDR) ('Bitdeer” or the 'Company”), a world-leading technology company for AI and Bitcoin mining infrastructure, today announced the launch of its latest self-developed mining machine, the SEALMINER DL1 Air. Optimized for the Scrypt algorithm, the DL1 Air provides a robust, industrial-grade solution for professional operators, supporting a range of coins headlined by Litecoin (LTC) and Dogecoin (DOGE).
JFB (NASDAQ: JFB) Announces XTEND and Rayonix Execute Exclusive Manufacturing and Distribution Agreement with Initial $11 Million Commitment to Expand XOS Platform into India.
Dallas, TX, March 16, 2026 (GLOBE NEWSWIRE) -- Vivakor, Inc. (OTC: VIVK) ('Vivakor” or the 'Company”), an integrated provider of energy transportation, storage, reuse, and remediation services, is pleased to announce that the Nasdaq Hearings Panel (the 'Panel') has granted the Company’s request for continued listing on the Nasdaq Stock Market, provided the Company regains compliance with Nasdaq’s $1.00 minimum bid price requirement by April 30, 2026 (the 'Bid Price Rule”). To regain compliance with the Bid Price Rule, the closing bid price of the Company’s common stock must be $1.00 or greater for ten consecutive trading days.
RONKONKOMA, N.Y., March 16, 2026 (GLOBE NEWSWIRE) -- SUNation Energy, Inc. (Nasdaq: SUNE) ('the Company”), a leading provider of sustainable solar energy and backup power solutions for households, businesses, and municipalities, today announced that it will issue its financial results for the fourth quarter and full year ended December 31, 2025 on Wednesday, March 18, 2026 after the close of the stock market. The Company will host a corresponding conference call on Thursday, March 19, 2026 at 9:00 a.m. ET, to discuss the results.
OTTAWA, ON, March 16, 2026 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO; CSE: DPRO; FSE: 3U8A) ('Draganfly” or the 'Company”), an award-winning, industry-leading developer of drone solutions and systems, today announced the successful completion of an exclusive Canadian Armed Forces (CAF) capabilities demonstration held on March 11 at Area XO in Ottawa, Ontario.
ENGLEWOOD CLIFFS, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Atlantic International Corp.(Nasdaq: ATLN), a global provider of outsourced services and workforce solutions, will be participating in the 38th Annual ROTH Conference being held March 22-24, 2026, at the Ritz Carlton in Dana Point, California.
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ('Company” or 'SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ('NeuroThera'), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc. ('Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).
DUBLIN and BRIDGEWATER, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular disease (CVD) worldwide, today announced that additional REDUCE-IT patient subgroup analysis and additional mechanistic data on potential multifactorial biologic activities will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March 28-30, 2026, in New Orleans, LA.